Olink

Olink®
Part of Thermo Fisher Scientific

Preoperative serum interleukin-6 and severe postoperative complications after colorectal cancer resection

International Journal of Colorectal Disease, 2026

Peroja P., Rintala J., Tuomisto A., Sirniö P., Mäkinen M., Väyrynen J.

Disease areaApplication areaSample typeProducts
Oncology
Surgical Complications
Patient Stratification
Plasma
Olink Target 96

Olink Target 96

Abstract

Purpose

To evaluate whether preoperative serum interleukin-6 (IL-6) is associated with severe postoperative complications after colorectal cancer resection.

Methods

This retrospective analysis included 474 patients undergoing curative-intent colorectal cancer resection at Oulu University Hospital between 2010 and 2020. Preoperative serum IL-6 was measured using the Olink Target 96 Immuno-Oncology panel and analysed as a continuous normalized protein expression (NPX) variable. The primary outcome was 90-day Clavien–Dindo classification (CD) grade IV–V complications. Secondary outcomes included overall, surgical, and non-surgical complications. Multivariable models were adjusted for age, sex, American Society of Anesthesiologists (ASA) class, Charlson Comorbidity Index, surgical approach, and tumor location. Bootstrap-based stability assessment was performed using 2000 resamples.

Results

Median preoperative IL-6 was 3.62 NPX. CD grade IV–V complications occurred in 28 patients (5.9%) and non-surgical complications in 134 patients (28.3%). After adjustment, higher IL-6 remained associated with CD grade IV–V complications (adjusted OR per 1-NPX increase 1.59, 95% CI 1.17–2.19) and non-surgical complications (adjusted OR 1.24, 95% CI 1.01–1.53). In exploratory incremental performance analysis, IL-6 alone showed discrimination comparable to the clinical model, with optimism-corrected AUCs of 0.780 and 0.750, respectively, and adding IL-6 to clinical variables increased the optimism-corrected AUC to 0.795, whereas the Brier score did not improve.

Conclusion

Higher preoperative IL-6 remained associated after adjustment with severe and non-surgical complications, but its incremental prognostic value was limited. IL-6 should be considered an exploratory marker of baseline vulnerability requiring direct evaluation in relation to frailty and external validation.

Read publication ↗